GoodRx Holdings, Inc. GDRX revenue by segment, product and geography
In its fiscal year ending 2025-12-31, GoodRx Holdings, Inc. reported revenue across 4 products and services; the largest, Prescription Transactions Revenue, was $544M, 68.3% of the filed sum (-5.8% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Prescription Transactions Revenue$544M68.3%-5.8% yoy
- Pharma Direct Revenue$151M19.0%+41.2% yoy
- Subscription Revenue$83.8M10.5%-3.2% yoy
- Other Revenue$17.7M2.2%-15.8% yoy
Members sum to the consolidated $797M for this period.
- Prescription Transactions Revenue$114M58.6%-23.7% yoy
- Pharma Manufacturer Solutions Revenues$52.2M26.9%+82.3% yoy
- Subscription Revenue$24.4M12.6%+16.1% yoy
- Other Revenue$3.69M1.9%-15.8% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.